Comparison of the Impact of Immune-Related Adverse Events Due to Immune Checkpoint Inhibitor Dual Combination Therapy and Immune Checkpoint Inhibitor Plus Tyrosine Kinase Inhibitor Combination Therapy in Patients with Advanced Renal Cell Carcinoma

Hiroki Ishihara(Tokyo Women's Medical University), Toshio Takagi(Tokyo Women's Medical University), Hidekazu Tachibana, Hirohito Kobayashi(Ebina General Hospital), Kazuhiko Yoshida(Tokyo Women's Medical University Hospital), Hironori Fukuda(Tokyo Women's Medical University), Kazutaka Nakamura(Tokyo Women's Medical University Hospital), Yasunobu Hashimoto, Yuki Nemoto(Tokyo Women's Medical University Adachi Medical Center), Tsunenori Kondo(Tokyo Women's Medical University Adachi Medical Center), Hiroaki Shimmura(Jyoban Hospital of Tokiwa Foundation), Junpei Iizuka(Tokyo Women's Medical University)
Targeted Oncology
December 26, 2022
Cited by 8


Related Papers